Results of a multi center observational study suggest that testing for a panel of genes may be the wave of the future for hereditary breast and ovarian cancer and alter the course of clinical management.
What are the current recommendations for managing women who are BRCA 1 or 2 carriers?
A new study looks at whether or not women with dense breasts require alternative screening methods. Conventional wisdom about reducing salt intake to lower blood pressure may not be correct. What's the impact of breastfeeding on reducing the recurrence of certain breast cancer types.
Clinical guidelines recently put forth by the American College of Physicians indicate that Pap tests should remain the mainstay of cervical cancer screening in average-risk patients under the age of younger than 30 with HPV testing reserved for older patient populations.
The Centers for Disease Control and Prevention (CDC) discusses the importance of HPV screening, vaccination, and the role of the clinician in helping prevent HPV and related cancers. The video presents three viewpoints: An OB-GYN who treats cervical cancer, a mother / Pediatrician who had her daughters vaccinated for HPV, and a survivor of cervical cancer.
Among BRCA mutation carriers, risk-reducing bilateral salpingo-oophorectomy (RRSO) results in an 80% reduction in risk of ovarian cancer and a 50% reduction in risk of breast cancer if the surgery is performed before the onset of menopause.
Menopause counseling hot flash: Persistent VMS more common in African-Americans and more new research
A review of the latest research on the persistence of vasomotor symptoms, the link between hormone therapy and ovarian cancer risk, and the prevalence of substance use in pregnant adolescents.
According to a new study in Gynecologic Oncology, women who have polycystic ovary syndrome (PCOS) may be at greater risk of developing some types of cancer.
An ADP-ribose polymerase (PARP) inhibitor has received accelerated approval from the US Food and Drug Administration (FDA) for treatment of women with heavily pretreated ovarian cancer associated with defective BRCA genes.